Penetrium Bioscience Inc.
A Hyundai Bioscience-affiliated biotech developing cancer drugs via its Penetrium(TM) platform, alongside CRO services.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2003 and listed on KOSDAQ in 2021, Penetrium Bioscience is a biotech drug developer acquired by Hyundai Bioscience Co., Ltd. in May 2024. It builds its pipeline around Penetrium(TM), a drug-delivery platform, while providing CRO services. Its bio TF team licensed drug-delivery tech from Hyundai Bioscience for breast/lung cancer drugs via a June 26, 2024 deal worth KRW 9.1bn upfront plus milestones.
Products & technology
- Contract Research Organization (CRO) ServiceClinical trial design, operation/management, data management and statistics, pharmacovigilance (PV), regulatory affairs (RA), and quality assurance (QA) for pharmaceutical/biotech clients across Phase 1-3 trials
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2020–2025 (Phase 1 1 · Phase 2a 1 · Phase 2 1)
- Phase 1Penetrium(TM)2025-12-09
1 trial site
- Phase 2aAP-1012021-12-29
1 trial site
- Phase 2CDA-012020-07-08
4 trial sites
R&D and key agreements
Source: DART corporate disclosure유방암 항암제 (약물전달체 기반) · 유방암 · Acquired a portion of exclusive patent license (Patent 10-2378590, held by C&Pharm and We Biotree) from Hyundai Bioscience under a June 26, 2024 Exclusive License Transfer Agreement: KRW 9.1bn upfront, KRW 6.5bn on US Phase 2 success, KRW 5.0bn on US Phase 3 success, KRW 5.0bn on US approval, plus running royalties of 3-10% of net sales by tier
폐암 항암제 (약물전달체 기반) · 폐암(비소세포폐암 등 고형암) · Exclusive license acquired from Hyundai Bioscience under the same June 26, 2024 agreement; prepared mass production of clinical-grade drug in cooperation with Daegu-Gyeongbuk Medical Innovation Foundation (K-Medi Hub) and Yuyoung Pharm
고형암 치료제 (약물전달체 기반, IND 1상) · 고형암(유방암·폐암 등) · IND 1상 승인(2025.12.09, 식품의약품안전처) · Received Investigational New Drug (IND) Phase 1 approval from the Ministry of Food and Drug Safety on December 9, 2025 (source sentence is truncated beyond this point)
Key disclosures
KRX KIND via OpenDARTShow 14 more events
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot67
- GoogleGoogleOther2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- PerplexityPerplexityBot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Penetrium Bioscience Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryPharma & CDMO
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition